Fmr LLC Tarsus Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 19,850 shares of TARS stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,850

Previous 18,935 4.83%

Holding current value

$1.39 Million

Previous $972,000 17.28%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$39.88 - $51.49 $36,490 - $47,113	915 Added 4.83%	19,850 $804,000
Q1 2025 May 12, 2025	SELL	$41.29 - $56.94 $614,890 - $847,950	-14,892 Reduced 44.02%	18,935 $972,000
Q4 2024 Feb 13, 2025	BUY	$32.27 - $55.37 $929,214 - $1.59 Million	28,795 Added 572.24%	33,827 $1.87 Million
Q3 2024 Nov 13, 2024	BUY	$21.54 - $34.6 $76,186 - $122,380	3,537 Added 236.59%	5,032 $165,000
Q2 2024 Aug 13, 2024	SELL	$25.17 - $38.73 $6,644 - $10,224	-264 Reduced 15.01%	1,495 $40,000
Q1 2024 May 13, 2024	BUY	$19.61 - $39.22 $2,784 - $5,569	142 Added 8.78%	1,759 $63,000
Q4 2023 Feb 13, 2024	BUY	$12.98 - $20.73 $6,658 - $10,634	513 Added 46.47%	1,617 $32,000
Q3 2023 Nov 13, 2023	BUY	$14.75 - $24.62 $4,115 - $6,868	279 Added 33.82%	1,104 $19,000
Q2 2023 Aug 11, 2023	SELL	$11.57 - $19.63 $3,482 - $5,908	-301 Reduced 26.73%	825 $14,000
Q1 2023 May 11, 2023	BUY	$11.92 - $16.27 $11,657 - $15,912	978 Added 660.81%	1,126 $14,000
Q4 2022 Feb 13, 2023	SELL	$14.12 - $18.72 $3,515 - $4,661	-249 Reduced 62.72%	148 $2,000
Q3 2022 Nov 10, 2022	BUY	$14.08 - $18.5 $3,787 - $4,976	269 Added 210.16%	397 $7,000
Q2 2022 Aug 12, 2022	BUY	$11.08 - $19.08 $930 - $1,602	84 Added 190.91%	128 $2,000
Q1 2022 May 13, 2022	BUY	$14.49 - $24.28 $637 - $1,068	44 New	44 $1,000

Others Institutions Holding TARS

# of Institutions

215

Shares Held

46.5M

Call Options Held

7.8K

Put Options Held

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.86B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account